← Leaderboards
Kent W Mouw
Dana-Farber Cancer Inst
$5,412,243
Attributed
$6,369,007
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2017–25$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,369,007 · 6
By mechanism
R01$4,579,291 · 3
R21$904,462 · 2
K08$885,254 · 1
Top collaborators
- Eliezer M Van Allen2 shared
- Srinivas Raghavan Viswanathan2 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Rameen Beroukhim$9,639,646
- Daphne A. Haas-Kogan$5,585,485
- Geoffrey I Shapiro$18,639,470
- Adam Nathaniel Boynton$199,514
- Eliezer M Van Allen$14,227,870
Others in their field
Other Emerging Leaders on “Property”
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Susan Abushakra · Alzheon, Inc.$47,265,244
- John Hobbs · Suny At Stony Brook$42,194,917
- Christopher Bee · Suny At Stony Brook$41,239,084
- John Damon Chodera · Sloan-Kettering Inst Can Research$39,689,447
- Eric C Palm · Florida State University$35,115,872
Research focus
PropertyTumorMutationCohortCancer PatientGenomicsResponseDna Repair PathwayMediatingCisplatinPathway InteractionsDna DamageMolecularChemotherapyBladder NeoplasmCellsMalignant Neoplasm Of Urinary BladderErcc2 GeneMalignant NeoplasmsBladderChemoradiationClinically RelevantCystectomyCancer Model
Grant awards (17)
Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer$866,727
R01 · FY2025 · CA · contact PI
Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder Cancer$725,117
R01 · FY2025 · CA
Dissecting and Targeting MAPK - PPARG Crosstalk in Bladder Cancer$487,506
R01 · FY2025 · CA · contact PI
Investigating Interactions Between Radiation and Antibody-Drug Conjugates in Bladder Cancer$246,784
R21 · FY2025 · CA · contact PI
Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder Cancer$736,801
R01 · FY2024 · CA
Dissecting and Targeting MAPK - PPARG Crosstalk in Bladder Cancer$497,544
R01 · FY2024 · CA · contact PI
Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer$411,213
R01 · FY2024 · CA · contact PI
Investigating Interactions Between Radiation and Antibody-Drug Conjugates in Bladder Cancer$206,067
R21 · FY2024 · CA · contact PI
Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer$422,255
R01 · FY2023 · CA · contact PI
Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer$432,128
R01 · FY2022 · CA · contact PI
Targeting the DNA Damage Response in CDK12-Mutant Prostate Cancer$243,938
R21 · FY2022 · CA · contact PI
Targeting the DNA Damage Response in CDK12-Mutant Prostate Cancer$207,673
R21 · FY2021 · CA · contact PI
Investigating the effect of ERCC2 mutations on DNA repair capacity and chemo-radiotherapy response in muscle-invasive bladder cancer$176,947
K08 · FY2021 · CA · contact PI
Investigating the effect of ERCC2 mutations on DNA repair capacity and chemo-radiotherapy response in muscle-invasive bladder cancer$176,947
K08 · FY2020 · CA · contact PI
Investigating the effect of ERCC2 mutations on DNA repair capacity and chemo-radiotherapy response in muscle-invasive bladder cancer$177,120
K08 · FY2019 · CA · contact PI
Investigating the effect of ERCC2 mutations on DNA repair capacity and chemo-radiotherapy response in muscle-invasive bladder cancer$177,120
K08 · FY2018 · CA · contact PI
Investigating the effect of ERCC2 mutations on DNA repair capacity and chemo-radiotherapy response in muscle-invasive bladder cancer$177,120
K08 · FY2017 · CA · contact PI